MedPath

Acella Pharmaceuticals, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

45

FDA:45

Drug Approvals

Ciclopirox

Approval Date
Jan 18, 2024
FDA

Prenaissance Plus

Approval Date
Jan 16, 2024
FDA

PNV-Select

Approval Date
Jan 16, 2024
FDA

Ciclopirox

Approval Date
Jan 16, 2024
FDA

Prenaissance

Approval Date
Jan 16, 2024
FDA

HYDROQUINONE 4%

Approval Date
Jan 15, 2024
FDA

Sodium Sulfacetamide 10 Sulfur 2 cream

Approval Date
Jan 15, 2024
FDA

PNV-DHA

Approval Date
Jan 15, 2024
FDA

PNV-DHA

Approval Date
Jan 15, 2024
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)
No trials found

News

FDA Approves Phase 2 Trial Modification for Abion's Novel Lung Cancer Combination Therapy

The FDA has approved modifications to the Phase 2 clinical trial for vabametkib, Abion's c-MET targeted anticancer drug, in combination with lazertinib for non-small cell lung cancer patients. The trial will evaluate this novel combination therapy in patients who have developed resistance to EGFR-targeted treatments, addressing a significant unmet need in NSCLC treatment.

© Copyright 2025. All Rights Reserved by MedPath